Non-invasive prenatal testing for detection of trisomy 13, 18, 21 and sex chromosome aneuploidies in 8594 cases by Zheng, Yunyun et al.
270
ORIGINAL PAPER /  OBSTE TRICS
Ginekologia Polska
2019, vol. 90, no. 5, 270–273
Copyright © 2019 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2019.0050
Corresponding author:
Jianfang Zhang
Obstetrics and Gynecology, The First Affiliated Hospital of AFMU (Air force Medical University), Xi’an, Shaanxi, 710032, China
e-mail: jianfangzhang17@sina.com
Non-invasive prenatal testing for detection  
of trisomy 13, 18, 21 and sex chromosome  
aneuploidies in 8594 cases
Yunyun Zheng, Shanning Wan, Yinghui Dang, Tingting Song, Biliang Chen, Jianfang Zhang
Department of Obstetrics and Gynecology, The First Affiliated Hospital Of AFMU (Air Force Medical University), Xi’an, Shaanxi, China
ABSTRACT
Objectives: Cell-free fetal DNA has been widely used in prenatal genetic testing during recent years. We explored the feasibility 
of non-invasive prenatal testing (NIPT) for analysis of common fetal aneuploidies among pregnancies in northwest China.
Material and methods: A total of 8594 maternal blood samples were collected from October 2014 to December 2017 in 
the Department of Obstetrics and Gynecology at the First Affiliated Hospital of the Air Force Medical University. Cases with 
positive screening results by NIPT detection were validated using karyotype analysis.
Results: Of 8594 clinical pregnancies, 88 had positive NIPT results and 78 of 88 (88.6%) positive NIPT results were shown 
to be false-positive by amniotic fluid puncture and chromosome karyotyping analysis. There were 44 cases (49.44%) with 
trisomy 21, 18, and 13 syndromes (30 cases of trisomy 21, 9 cases of trisomy 18, and 5 cases of trisomy 13). There were 
44 cases (50.56%) with sex chromosome abnormalities, including 11 cases with Turner syndrome (45, X), 17 cases with 
Triple X syndrome (47, XXX), 2 cases with Klinefelter syndrome (47, XXY), and 14 cases with 47, XYY syndrome (47, XYY).
Conclusions: The accuracy, specificity, high efficiency, and acceptance of NIPT can effectively avoid birth defects and 
improve the quality of the birth population. We should deepen mining and analysis of the clinical data and explore ways 
to use NIPT. It is recommended that the NIPT guidelines be extended to low-risk patients to further explore the impact of 
a significant increase in screening.
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INTRODUCTION
In 1997, cell-free fetal DNA fragments were discovered 
in maternal blood, and in 2011 non-invasive prenatal test-
ing (NIPT) analyzed cell-free fetal DNA via massive parallel 
sequencing. The testing was introduced into clinical prac-
tice and became more widely available [1], Clinical trial 
data and reports based on actual clinical experience have 
demonstrated efficacy in screening for the most common 
autosomies that occur at birth (trisomies 21, 18, and 13), 
and sex chromosome aneuploidies [2–5]. Some studies 
have reported a detection and false-positive rates of 99.2% 
and 0.09% for trisomy 21, 96.3% and 0.13% for trisomy 18, 
and 91.0% and 0.13% for trisomy13 [6]. Other studies have 
reported trisomy 21 detection rates of 98.6% to > 99% [7–9], 
and the trisomy 18 detection rate is > 97.2% [8]. According 
to a meta-analysis conducted by Taylor-Phillip et al. [10], the 
pooled sensitivity was 99.3% for trisomy 21, 97.4% for tri-
somy 18, and 97.4% for trisomy13. Positive predictive values 
are significantly lower, particularly in low-risk populations 
[11]. Therefore, NIPT is an accurate screening test that offers 
the opportunity to improve the detection of aneuploidies, 
while reducing the use of invasive diagnostic procedures.
In our hospital we have used NIPT since 2014 and > 8594 
pregnant women have undergone NIPT. We mined and 
analyzed the clinical data and showed that NIPT is feasible 
for prenatal screening of common chromosomal abnormali-
ties. Herein we explored the use of NIPT from the perspective 
of evidence-based medicine.
MATERIAL AND METHODS
Non-invasive prenatal testing
A total of 8594 pregnant women who underwent NIPT 
and prenatal diagnosis at the First Affiliated Hospital of the 
Air Force Medical University from October 2014 to Decem-
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ber 2017 were enrolled in this study. The inclusion criteria 
were as follows: (i) singleton pregnancy; (ii) 18–50 years 
of age; and (iii) gestational age 13–27 weeks. All patients 
had a risk indication, which included advanced maternal 
age ( ≥ 35 years), a sonographic abnormality, a history of 
a prior aneuploidy, and abnormal traditional aneuploidy 
screening. Informed consent was obtained from the pa-
tients prior to enrollment in the study. Standard procedures 
were followed, including plasma separation, isolation of 
cell-free DNA, library construction (end repair, joint con-
nection, and gap repair), an accurate quantitative library, 
sequencing detection, and bioinformatics analysis. An Il-
lumina NextSeq CN500 or Ion Torrent Sequencing System 
(BioelectronSeq 4000) was used for sequencing detection. 
Sequencing data were analyzed using a proprietary al-
gorithm. The binary hypothesis Z-score of specific chro-
mosomes in each sample was determined; the normal 
range for chromosomes was 3 < z < 3. Briefly, samples with 
a Z-score ≥ 3.0 for these chromosomes was classified as 
positive, whereas a Z-score < 3.0 was classified as negative 
for the indicated trisomy.
Invasive procedure and karyotyping
Pregnant women with positive screening results on 
NIPT consented to undergo an invasive prenatal diagnosis 
procedure, which is the gold standard for diagnosing chro-
mosome aneuploidies. Karyotyping was performed on cell 
cultures from trophoblastic or fetal cells. Routine fixation, 
production and dyeing treatment, microscopic examination, 
and analysis of the karyotype (G-banding) of amniotic fluid 
were performed. The resolution of metaphase G-banding 
was 320 bands. 
Follow-up
Prenatal and postnatal telephone follow-up were con-
ducted to determine whether or not there were false-neg-
ative results.
Statistical analyses
All statistical analyses were performed using SPSS 19.0 soft-
ware. Data are presented as the mean + SD. Analysis of vari-
ance was used to compare the differences between different 
groups. A P-value < 0.05 was considered statistically significant.
RESULTS
Efficiency of NIPT for T21/T18/T13
Among 8594 prenatal women who received effective 
NIPT results, 44 had positive results for T21/T18/T13, including 
30 cases with T21, 9 cases with T18, and 5 cases with T13. After 
informed consent, the gravidas accepted prenatal diagnosis 
by amniotic fluid cell analysis. Table 1 shows the prenatal 
diagnosis results. The detection rate, specificity, and positive 
predictive value (PPV) was 97.37%, 99.92%, and 82.22%, re-
spectively. After follow-up, we identified 1 false-negative result 
and 7 false-positive results; the false-positive rate was 0.08%.
Efficiency of NIPT for sex chromosome 
aneuploidy (SCA) 
The NIPT results indicated that 44 cases had fetal sex 
chromosome abnormalities, including 2 cases with Kline-
felter syndrome (47, XXY), 11 cases with Turner syndrome 
(45, X), 14 cases with 47 XYY syndrome, and 17 cases with 
XXX syndrome (47, XXX). After informed consent, 33 gravidas 
accepted prenatal diagnosis via amniocentesis. As shown in 
Table 2, 18 cases were confirmed to be true-positive results 
Table 1. 44 cases of NIPT-positive results for T21/T18/T13 
NIPT result NIPT positive result True positive False positive False negative Detection rate [%] Specificity [%]
Positive predictive 
value [%]
T21 30 30 0 1 96.77% 100% 96.77%
T18 9 6 3 0 100% 100% 66.67%
T13 5 1 4 0 100% 100% 20.00%
Total 44 37 7 1  97.37% 99.92% 82.22%
Table 2. 44 cases of NIPT-positive SCA detection results 
NIPT-positive 
SCA
Positive NIPT 
cases [n]
Karyotype 
validated True positive False positive
Positive predictive 
value [%]
Without
karyotype validated
47, XXY 2 2 2 0 100.00% 0
45, X 11 9 4 5 44.44% 2
47, XYY 14 10 5 5 50.00% 4
47, XXX 17 12 7 5 58.33% 5
Total 44 33 18 15 54.55% 11
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and 15 cases were confirmed to be false-positive results. The 
PPV of NIPT for fetal SCAs was 54.55%. Table 3 shows the 
PPV of NIPT for different types of SCAs. The PPV for Turner 
syndrome was the lowest (44.44%).
Distribution of the indications
Among 8594 prenatal women who received NIPT re-
sults, we diagnosed a total of 88 cases with abnormal NIPT 
results. Different detection pointers detect different positive 
NIPT numbers. The positive distribution of each indication 
through NIPT was different (Tab. 3).
DISCUSSION
Aneuploidies, which are chromosomal abnormalities 
characterized by anomalous of chromosomes than the 
23 pairs normally present in humans,concluding Down 
syndrome (trisomy 21 or T21), Edward syndrome (trisomy 
18 or T18), Patau syndrome (trisomy 13 or T13), Turner 
syndrome (45, X), Klinefelter syndrome (47, XXY), Triple X 
syndrome (47, XXX) and 47, XYY syndrome (47, XYY). These 
chromosomal anomalies are contributed to the morbidity or 
death of both childhood and adulthood. [12] During recent 
years, NIPT has been increasingly used in the detection 
of common chromosome aneuploidies for T21, T18, and 
T13 in fetuses during prenatal screening in many countries 
[13]. NIPT is helpful for the early detection of birth defects 
to reduce the incidence of birth defects. In addition, it 
can reduce the occurance of spontaneous miscarriages 
due to invasive prenatal testing such as amniocentesis and 
expand the prenatal testing options as well as reduce the 
need for invasive testing [14–17].
According to our clinical data from 8594 gravidas, we 
confirmed that the detection rate, specificity, and PPV were 
97.37%, 99.92%, and 82.22%, respectively, which were in ac-
cordance with other studies [16–19]. Moreover, the specific-
ity of the prior serologic screening test for T21 was 29.13% 
compared to 100% for NIPT; the PPV was 96.77%. Compared 
with conventional methods, the specificity and PPV of NIPT 
in screening for T21 were greater. For T18, the specificity 
was 98.20% for conventional screening [20] compared to 
100% for NIPT; the PPV was 66.77%. The PPV for T13 was 
20.00%; the result was not satisfactory, suggesting that 
large samples are still needed to focus on the performance 
of NIPT for T13 screening.
NIPT is used in prenatal screening for fetal SCAs; however, 
positive SCA results are not a direct indication to induce 
labor. Our results were positive for SCAs in 44 cases; there 
were 18 true-positive cases. The overall true-positive rate 
for SCA detection by NIPT was 54.55 %. Among the different 
types of SCAs, the PPV for Turner syndrome was the lowest 
(44.44%). Prediction of other SCAs was relatively accurate; 
the PPVs of pregnancies with 47, XXX, 47, XXY, and 47, XYY 
karyotypes predicted by NIPT were 58.33%, 100%, and 
50.00%, respectively. Cheung [21] reported that the false-
positive rate of monosomy X karyotype detected by NIPT was 
62%, which is much higher compared to the false-rates for 47, 
XXX, 47, XXY, and 47, XYY karyotypes. Therefore, our findings 
demonstrated that NIPT was a more accurate predictor 
of triple X and Klinefelter syndrome compared with fetal 
Turner syndrome. In addition, patients with SCAs are usually 
mildly symptomatic during the neonatal period without any 
physical or intellectual disabilities. The traditional method of 
follow-up could not achieve accurate results of SCAs disease. 
Therefore, it is necessary to improve the detection rate of sex 
chromosomes by NIPT and reduce the false-positive rate.
Our results suggest that NIPT is suitable for high- and 
intermediate-risk prenatal screening. It has been reported 
that among 56 Down syndrome fetuses, 14% were 
associated with intermediate-risk mothers [22]. In our study, 
NIPT for intermediate-risk samples detected 10 positive 
cases, among which 7 were true positive (70.00%). NIPT for 
low-risk samples detected 12 positive cases, among which 
7 were true positive (58.33%).
The current experimental studies involving clinical 
effectiveness have focused on high-risk populations, 
such as advanced maternal age, and screening to reduce 
unnecessary interventional prenatal diagnosis, which have 
not been fully validated in low-risk populations. Based on 
our data, the experimental failure rate was not significantly 
increased in low-risk groups and the false-positive rate 
Table 3. The positive distribution of each indication for 88 cases with NIPT positive results
Indication Cases [%] Positive NIPT cases [%] True positive [%]
High-risk prenatal screening 2614 (30.42%) 32(35.95%) 20 (60.61%)
Intermediate-risk prenatal screening 2111 (24.56%) 10 (11.24%) 7 (70.00%)
Low-risk prenatal screening 1513 (17.61%) 12 (13.48%) 7 (58.33%)
Ultrasound structural abnormality 572 (15.65%) 9 (10.11%) 6 (66.67)
Advanced maternal age ( ≥ 35) 973 (11.32%) 19 (1.95%) 11 (57.89%)
Abnormal pregnancy 590 (6.87%) 5 (21.35%) 3 (60.00%)
Assisted reproduction conception 221 (2.57%) 2 (2.25%) 1 (50.00%)
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was similar to the high-risk group. It is our opinion that 
if guidelines expand NIPT recommendations to include 
low-risk patients, the implications of significantly increased 
screening should be further explored.
The development and application of NIPT in 
southern and southeastern China has advanced further 
than in western and northern China; there are clearly 
regional differences in the use of NIPT [23]. Our study was 
conducted mainly in northwestern China. We found that 
there were fewer pregnant women undergoing NIPT, with 
the main reason being cost. The costs for NIPT screening 
are currently higher than for other screening protocols 
[24]. If the technology can reduce the cost of testing, more 
pregnant women will undergo NIPT and will gradually 
replace serologic screening. 
The accuracy, specificity, high efficiency, and acceptance 
of NIPT has great advantages, which can effectively avoid 
the birth defects and improve the quality of the birth 
population compared with the classical invasion testing. 
But the disadvantage of NIPT is obvious. The false positives 
could occur because of NIPT [17]. On this account, we must 
use invasive testing to confirm positive results before any 
irreversible procedure is performed. It can avoid the harm 
of patients’ interests from detection errors [12].
CONCLUSIONS
We should deepen mining and analysis of the clinical 
data and explore ways to use NIPT. It is recommended that 
the NIPT guidelines be extended to low-risk patients to 
further explore the significance of a significant increase in 
screening and we can consider NIPT as an important supple-
mentary diagnosis to conventional invasion testing for detec-
tion of trisomy 13, 18, 21 and sex chromosome aneuploidies.
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